Cytox Plans US Clinical Launch for Early-Stage Alzheimer's Test While Courting Pharma Partners
May 03, 2017 Justin Petrone www.genomeweb.com British molecular diagnostics company Cytox plans to make…
read moreCytox is developing a diagnostic test and therapeutic cures for Alzheimer’s Disease which is estimated to affect 15 million people worldwide. The company is a university spin-out based on groundbreaking academic research into the role of the cell cycle in neuro-degenerative diseases.
Status current
Associated Fund
Advantage Growth Fund,
UK Innovation & Science Seed Fund
Sector Medical / Biotechnology
Website www.cytoxgroup.com
May 03, 2017 Justin Petrone www.genomeweb.com British molecular diagnostics company Cytox plans to make…
read more20 July 2015: Oxford, UK. Cytox Ltd, an innovative developer of assays for risk assessment…
read more